作者
Matthew J Price, Peter B Berger, Paul S Teirstein, Jean-François Tanguay, Dominick J Angiolillo, Douglas Spriggs, Sanjeev Puri, Mark Robbins, Kirk N Garratt, Olivier F Bertrand, Michael E Stillabower, Joseph R Aragon, David E Kandzari, Curtiss T Stinis, Michael S Lee, Steven V Manoukian, Christopher P Cannon, Nicholas J Schork, Eric J Topol, Gravitas Investigators
发表日期
2011/3/16
期刊
Jama
卷号
305
期号
11
页码范围
1097-1105
出版商
American Medical Association
简介
Context
High platelet reactivity while receiving clopidogrel has been linked to cardiovascular events after percutaneous coronary intervention (PCI), but a treatment strategy for this issue is not well defined.
Objective
To evaluate the effect of high-dose compared with standard-dose clopidogrel in patients with high on-treatment platelet reactivity after PCI.
Design, Setting, and Patients
Randomized, double-blind, active-control trial (Gauging Responsiveness with A VerifyNow assay—Impact on Thrombosis And Safety [GRAVITAS]) of 2214 patients with high on-treatment reactivity 12 to 24 hours after PCI with drug-eluting stents at 83 centers in North America between July 2008 and April 2010.
Interventions
High-dose clopidogrel (600-mg initial dose, 150 mg daily thereafter) or standard-dose clopidogrel (no additional loading dose, 75 mg daily) for 6 months.
Main Outcome Measures
The primary end point was the 6-month …
引用总数
学术搜索中的文章
MJ Price, PB Berger, PS Teirstein, JF Tanguay… - Jama, 2011